The invention relates to detection of drug insensitivity by detecting mutations in the p97 gene or the p97 gene product following treatment with a p97 inhibitor, and identification of drugs to overcome such drug insensitivity.

Disclosed are compositions and methods for treating nephrogenic diabetes insipidus and for induction of diuretic effect.

The present disclosure is directed to a modified plant cell, plant tissue, plantlet, plant part, plant, and progeny thereof containing a combination of apyrase genes, including at least one modified gene and/or at least one additional apyrase gene. The disclosure is also directed to a method of making a modified plant with a modified apyrase gene and/or an additional apyrase gene. The modified plant generally exhibits at least one improved characteristic over the plant line from which it was derived. The disclosure also relates to a recombinant DNA molecule comprising a nucleotide sequence encoding an apyrase enzyme as disclosed.

The invention relates to design and therapeutic use of solubilized apyrase polypeptides, pharmaceuticals compositions, therapeutic uses and methods useful for preventing and treating tissue damage.

Provided herein are solubilized apyrase polypeptides, nucleotides encoding such solubilized apyrase polypeptides, pharmaceutical compositions containing such solubilized apyrase polypeptides, therapeutic uses of such solubilized apyrase polypeptides. Also provided herein are methods useful for preventing or treating tissue damage, e.g., by administering a solubilized apyrase polypeptide or pharmaceutical composition thereof, and methods for producing such solubilized apyrase polypeptides.

The present disclosure is directed to a modified plant cell, plant tissue, plantlet, plant part, plant, and progeny thereof containing a combination of apyrase genes, including at least one modified gene and/or at least one additional apyrase gene. The disclosure is also directed to a method of making a modified plant with a modified apyrase gene and/or an additional apyrase gene. The modified plant generally exhibits at least one improved characteristic over the plant line from which it was derived. The disclosure also relates to a recombinant DNA molecule comprising a nucleotide sequence encoding an apyrase enzyme as disclosed.

The present disclosure relates to cells, tissues, organs, and/or animals having one or more modified genes for enhanced xenograft survival and/or tolerance. In addition, the present disclosure relates to methods of making and using the cells, tissues, organs, and/or animals having one or more of the modified genes.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

Provided herein, inter alia, are compositions and methods for expressing recombinant phosphatases containing numerous disulfide bonds in host cells.

Compositions and methods for treating hemorrhagic shock, multiple organ failure resulting from hemorrhagic shock, and organ complications resultant therefrom such as acute respiratory distress syndrome.